We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

51 hedge funds and large institutions have $60.7M invested in Invesco Biotechnology & Genome ETF in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 3

49% more capital invested

Capital invested by funds: $40.7M → $60.7M (+$20M)

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

28% more funds holding

Funds holding: 40 → 51 (+11)

2.04% more ownership

Funds ownership: 25.67% → 27.71% (+2%)

Holders
51
Holders Change
+11
Holders Change %
+27.5%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
13
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Niemann Capital Management
Nevada
+$3.34M
2
Morgan Stanley
Morgan Stanley
New York
+$2.2M
3
PFG
Pacific Financial Group
Washington
+$1.88M
4
LPL Financial
LPL Financial
California
+$910K
5
WA
WFG Advisors
Texas
+$833K

Top Sellers

Rank Fund Capital Flow
1
GC
Guggenheim Capital
Illinois
-$1.31M
2
SAM
SignalPoint Asset Management
Missouri
-$765K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$117K
4
WB
Webster Bank
Connecticut
-$43.1K
5
RJA
Raymond James & Associates
Florida
-$32.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$245K -$16.6K -500 -7%
CIC
27
Carnegie Investment Counsel
Ohio
$240K +$227K +6,850 New
CAN
28
Cetera Advisor Networks
California
$206K +$192K +5,810 New
MAA
29
Managed Account Advisors
New Jersey
$155K +$56.8K +1,714 +63%
LTFS
30
Ladenburg Thalmann Financial Services
Florida
$146K +$41.7K +1,259 +43%
Citigroup
31
Citigroup
New York
$77K – – –
OIA
32
Optimum Investment Advisors
Illinois
$46K +$43.9K +1,325 New
AIG
33
American International Group
New York
$45.8K +$14.1K +426 +48%
NES
34
New England Securities
New York
$35K -$1.32K -40 -4%
BC
35
Bartlett & Co
Ohio
$35K – – –
Bank of Montreal
36
Bank of Montreal
Ontario, Canada
$35K +$33.1K +1,000 New
1IC
37
1919 Investment Counsel
Maryland
$29K +$26.5K +800 New
FANJ
38
Financial Architects (New Jersey)
New Jersey
$26K – – –
Ameriprise
39
Ameriprise
Minnesota
$25K +$23.2K +700 New
Nomura Holdings
40
Nomura Holdings
Japan
$24K +$22.7K +684 New
LFR
41
Lehman Financial Resources
Pennsylvania
$21K – – –
PSI
42
Pinnacle Summer Investments
Virginia
$18K – – –
Fifth Third Bancorp
43
Fifth Third Bancorp
Ohio
$18K +$16.6K +500 New
MAS
44
Madden Advisory Services
Florida
$14K – – –
DADC
45
D.A. Davidson & Co
Montana
$9K – – –
Creative Planning
46
Creative Planning
Kansas
$7K -$6.62K -200 -50%
PAS
47
Partnervest Advisory Services
California
$7K – – –
MFS
48
MSI Financial Services
Massachusetts
$6K -$3.31K -100 -38%
AA
49
Apriem Advisors
California
$4K – – –
SMA
50
Simply Money Advisors
Ohio
$4K +$3.97K +120 New
1
2
3

PBE Hedge Fund Activity: Q3 2013 in Review

51 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2013, worth a combined $60.7M — up 49% from $40.7M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PBE positions and 3 closed out — a net gain of 11 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Niemann Capital Management, opening a new position worth an estimated $3.34M. The largest seller was Guggenheim Capital, exiting entirely with an estimated $1.31M sold.

  • 51 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2013, up from 40 in Q2 2013.
  • Funds reported $60.7M of Invesco Biotechnology & Genome ETF stock for Q3 2013, up 49% quarter-over-quarter.
  • 14 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2013 and 3 closed out, a net change of +11 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q3 2013 was Niemann Capital Management, an estimated $3.34M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q3 2013 was Guggenheim Capital, an estimated $1.31M sold.

Based on aggregated 13F filings for Q3 2013.